The UK has a voluntary agreement that was struck by the government and NHS England (now referred to as NHSE&I) with the Association of the British Pharmaceutical Industry (ABPI) in 2018
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
